FDA Guide Cuts Animal Testing for New Drugs
Published Date: 3/19/2026
Notice
Summary
The FDA just dropped a draft guide to help drug makers use new, smarter testing methods that can reduce animal testing and better predict human safety. This affects drug developers who want to submit safer, more reliable data for approval. Comments are open until May 18, 2026, so get involved early to shape the final rules and possibly save time and money in drug development.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
FDA Encourages Use of NAMs in Submissions
If you develop drugs, FDA published a draft guidance that gives a validation framework and general recommendations for using new approach methodologies (NAMs) in drug development. The guidance covers using nonclinical NAM data to support regulatory submissions (for example, investigational new drug applications and biologics license applications), encourages early engagement with drug review divisions, and is open for comment through May 18, 2026.
NAMs Apply to OTC Topical Monograph Orders
If you make nonprescription topical (OTC) drugs, the draft guidance says NAMs can be used to support nonclinical data for OTC monograph orders issued under section 505G of the FD&C Act. FDA issued this draft guidance in part to satisfy the requirement under section 505G(r)(2)(B), and it is open for comment through May 18, 2026.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13778 — Medical Device User Fee Amendments; Public Meeting; Request for Comments
The FDA is planning a public meeting on August 5, 2026, to talk about renewing fees that medical device makers pay to help speed up device reviews from 2028 to 2032. This affects companies making medical devices and could impact how much they pay and how fast their products get approved. The current fee program ends in September 2027, so the FDA wants your thoughts before finalizing new rules and fees.
2026-13716 — New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of Sponsor
The FDA just updated the rules for new animal drugs, approving several new and generic medicines for pets and farm animals from early 2026. These changes help keep animal treatments safe and effective, and the updates take effect right away on July 7, 2026. If you’re a drug maker or animal caretaker, these approvals and sponsor changes could impact what medicines are available and when.
2026-13616 — Endo Operations Limited, et al.; Withdrawal of Approval of 34 New Drug Applications
The FDA is officially pulling the plug on 34 drug approvals because the companies stopped selling these medicines. This change kicks in on August 5, 2026, and it mainly affects drug makers like Endo Operations and Pfizer. No money penalties here—just a clean break, but companies can ask to reapply if they want to bring the drugs back.
2026-13534 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Administrative Practices and Procedures; Formal Hearings
The FDA is asking for public feedback on how it collects information for formal hearings and administrative rules. This affects businesses and people who interact with the FDA, with no new costs but a chance to improve paperwork processes. Comments are due by August 5, 2026, so don’t miss your chance to weigh in!
2026-13533 — Agency Information Collection Activities; Proposed Collection; Comment Request; Biologics License Applications, Procedures and Requirements
The FDA wants your thoughts on how it collects info for biologics license applications—basically, the paperwork needed to approve new biological medicines. This affects companies making these medicines and anyone involved in the approval process. You’ve got until September 4, 2026, to share your comments, so don’t miss out on shaping the rules and possibly saving time and money!
Previous / Next Documents
Previous: 2026-05389 — Agency Information Collection Activities; Submission to the Office of Management and Budget (OMB) for Review and Approval; Comment Request; CHIPS Workforce Solution Participant Data Collection
The Department of Commerce is asking for public feedback on a new data collection for the CHIPS Workforce Solution program, which helps track how semiconductor companies use workforce funding. This affects companies receiving CHIPS funds and aims to make reporting easier while ensuring the government gets useful info. Comments are open until May 18, 2026, so don’t miss your chance to weigh in!
Next: 2026-05391 — 60-Day Notice of Proposed Information Collection: Risk Analysis and Management (RAM) OMB Control Number 1405-0204
The Department of State wants to keep collecting info from contractors and grantees to help manage risks better. They’re asking for public feedback by May 18, 2026, before renewing this paperwork, which takes about 1.5 hours per response. This update won’t cost you money but helps keep things safe and smooth for everyone involved.